Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.
IPO Year: 1999
Exchange: AMEX
Website: palatin.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/24/2021 | $2.00 → $5.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4/A - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.
Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end of calendar year 2024 Additional studies under assessment for multiple metabolic conditions
HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.
SC 13G/A - PALATIN TECHNOLOGIES INC (0000911216) (Subject)
SC 13G - PALATIN TECHNOLOGIES INC (0000911216) (Subject)
CRANBURY, N.J., May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 15, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q3 Fiscal Yea
On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025)Multiple Secondary Symptom Endpoints Met, Statistical Significance (P<0.025)On an Intent-to-Treat Analysis, Co-Primary Sign Endpoint and Secondary Sign Endpoints Not MetPL9643 Demonstrated Superiority Over Vehicle in Multiple Sign EndpointsExcellent Safety and Tolerability ProfileFuture Discussions Planned with FDA Regarding Regulatory Approval PathCompany to Host Conference Call at 8:30 a.m. ET TodayCRANBURY, N.J., Feb. 28, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of
CRANBURY, N.J., Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q2
Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder (HSDD) Vyleesi® has experienced 8 Consecutive Quarters of Double-Digit Prescription Growth Acquisition Adds Another Commercial Stage, Patent Protected Product to Cosette's Rapidly Expanding Women's Health Portfolio Cosette Pharmaceuticals, Inc. ("Cosette"), a US-based specialty pharmaceutical company with a focus on women's health and cardiovascular medicines, has completed the acquisition of Vyleesi® from Palatin Technologies, Inc. (NYSE:PTN), which includes 5 Orange Book listed patents with protection up to 2041. Palatin and Cosette will ens
Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients EnrolledTopline Data Expected Late 4Q Calendar Year 2023Interim Analysis of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye Excellent Patient Safety and Tolerability Product ProfilePhase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Interim Analysis Targeted for 1Q Calendar Year 2024Topline Results Currently Expected First Half Calendar Year 2024Vyleesi®Net Product Revenue Increased 47% Over the Prior QuarterPrescriptions Dispensed Increased 16% Over the Prior Quarter6 Consecutive Quarters of Double-Di
CRANBURY, N.J., Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 28, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audi
Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL EventAnalysis of Lead-In Population of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye along with Excellent Patient Safety and Tolerability Final Data Expected Second Half Calendar Year 2023Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Interim Analysis Targeted for Second Half Calendar Year 2023 Topline Results Currently Expected First Half Calendar Year 2024Vyleesi®Net Product Revenue Increased 16% Over the Prior QuarterPrescriptions Dispensed Increased 27% Over the Prior Quarter5 Consecutive Quarters of Double-Digit Growth
CRANBURY, N.J., May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 16, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q3 Fiscal Year
CRANBURY, N.J., Feb. 10, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2023, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast
CRANBURY, N.J., Nov. 9, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2022, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q1
Dry Eye Disease (DED): PL9643MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical StudiesFDA Confirms Protocols and EndpointsTargeting Enrollment Start in 4Q Calendar Year 2024Topline Results Anticipated 4Q Calendar Year 2025Potential Collaboration/Funding Discussions OngoingObesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist + Glucagon Like Peptide-1 (GLP-1)Patient Dosing Commenced 3Q Calendar Year 2024Topline Results Expected 1Q Calendar Year 2025Male Sexual Dysfunction: Development and Clinical Program with Bremelanotide Co-Formulated with a PDE5i for the Treatment of Erectile Dysfunction (ED) in Patients That Do Not Respond to PDE5i MonotherapyPharmacokinetics Study Expec
FDA & Palatin agree on clear regulatory path for PL9643 NDA submission in DEDFDA confirms acceptability of protocols and endpoints for remaining MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Trials in DEDCurrently anticipate patient enrollment to start in 4Q calendar year 2024Topline results currently expected in 4Q calendar year 2025CRANBURY, N.J., Aug. 28, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced receipt of FDA correspondence confirming the acceptability of the protocols and endpoints for signs and symptoms of P
Complete enrollment currently expected in 3Q 2024Topline results expected in 1Q calendar year 2025Additional studies under assessment for multiple metabolic conditionsCRANBURY, N.J., Aug. 22, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the T
CRANBURY, N.J., June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant inducement agreement with an institutional investor to exercise certain outstanding warrants that the Company issued in November 2022 and October 2023 totaling 3,233,277 shares of the Company's common stock for gross proceeds of approximately $6.1 million. Pursuant to th
In ED patients that do not respond to PDE5i monotherapy~30-40% of ED patients do not respond to PDE5i treatmentData from this Phase 2 clinical study is expected by end of calendar year 2024Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5iPhase 3 clinical study with new co-formulated bremelanotide plus a PDE5i in ED patients that do not respond to PDE5i monotherapy expected to start in the 1st half of calendar year 2025CRANBURY, N.J., June 20, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocor
Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end of calendar year 2024Additional studies under assessment for multiple metabolic conditionsCRANBURY, N.J., June 12, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the initiation of a Phase 2 clinical study of bremelanotide for the treatment of obesity. The clinical study will evaluate the safety and efficacy of bremelanotide, a melanocortin 4 receptor (M
Positive Phase 3 PL9643 MELODY-1 Pivotal Study ResultsCo-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Symptom Endpoints Met Statistical Significance (P<0.05), at the12-Week Treatment PeriodRapid Onset of Efficacy and Multiple Symptom Endpoints, Including the Co-Primary Pain Endpoint, Met Statistical Significance (P<0.05) at the 2-Week Treatment Period and Continued to Improve Over the 12-Week Treatment PeriodAt the 2-Week Treatment Period, Multiple Sign Endpoints, Including All 4 Fluorescein Staining Endpoints, Met Statistical Significance (P<0.05)Excellent Safety and Tolerability ProfileOral Phase 2 PL8177 Clinical Study in Patients with Ulce
CRANBURY, N.J., May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 15, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q3 Fiscal Yea
Phase 2 clinical study expected to begin in mid-calendar year 2024Topline data expected by calendar year-end 2024Hosting virtual KOL event "Beyond GLPs" on May 8, 2024 Focus will be on Company's metabolic program and the multiple roles for novel melanocortin receptor 4 agonists in treating obesity and weight loss maintenanceCRANBURY, N.J., May 2, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the investigational new drug (IND) applicati
CRANBURY, N.J., April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a virtual KOL event on Wednesday, May 8, 2024 at 10:00 AM ET. To register, click here. The event will feature Jesse Richards, DO (Oklahoma State University College of Osteopathic Medicine), who will discuss the current treatment landscape for obesity, the need for new treatments with alternative mechanisms of action and
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
S-1 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
ARS - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
DEF 14A - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
10-Q - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
EFFECT - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
424B3 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)